| [1] |
National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: breast cancer. version 1.2018 [EB/OL]．[2018-04-03]．
URL
|
| [2] |
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2017版)[J]. 中国癌症杂志，2017，27(9)：695-759.
|
| [3] |
Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages Ⅰ and Ⅱ invasive breast cancer [J]. J Clin Oncol, 2014, 32(14): 1507-1515.
|
| [4] |
Morrow M, Van Zee KJ, Solin LJ, et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ [J]．Ann Surg Oncol, 2016, 23(12): 3801-3810.
|
| [5] |
Galimberti V, Cole BF, Zurrida S, et al International Breast Cancer Study Group trial 23-01 investigators. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial[J]. Lancet Oncol, 2013, 14(4): 297-305.
|
| [6] |
Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) randomized clinical trial[J]. JAMA, 2017, 318(10): 918-926.
|
| [7] |
Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial[J]．Lancet Oncol, 2014, 15(12): 1303-1310.
|
| [8] |
Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18[J]. J Clin Oncol, 1997, 15(7): 2483-2493.
|
| [9] |
Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27[J]. J Clin Oncol, 2003, 21(22): 4165-4174.
|
| [10] |
Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study[J]. Lancet Oncol, 2013, 14(7): 609-618.
|
| [11] |
Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: The SN FNAC study[J]. J Clin Oncol, 2015, 33(3): 258-264.
|
| [12] |
Boughey JC, Suman VJ, Mittendorf EA, et al. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance) [J]. Ann Surg, 2015, 261 (3): 547-552.
|
| [13] |
Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31 [J]. J Clin Oncol, 2011, 29(25): 3366-3373.
|
| [14] |
Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer [J]．N Engl J Med, 2011, 365(14): 1273-1283.
|
| [15] |
von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer [J]．N Engl J Med, 2017, 377(2): 122-131.
|
| [16] |
Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial [J]．Lancet Oncol, 2017, 18(12): 1688-1700.
|
| [17] |
Tolaney SM, Barry WT, Dang CT et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer [J]. N Engl J Med, 2015, 372(2): 134-141.
|
| [18] |
Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer [J]．N Engl J Med, 2016, 375(20): 1925-1936.
|
| [19] |
Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer [J]．N Engl J Med, 2016, 375(18): 1738-1748.
|
| [20] |
Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer[J]. J Clin Oncol, 2017, 35(32): 3638-3646.
|
| [21] |
Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial [J]. Lancet, 2016, 388(10063): 2997-3005.
|